Noradrenalin Aguettant (Noradrenaline Tartrate)

After intravenous administration, Noradrenaline Tartrate is converted to noradrenaline, which activates alpha‑1 adrenergic receptors causing vasoconstriction and beta‑1 receptors increasing heart rate and contractility. This dual action raises systemic vascular resistance and cardiac output, helping restore adequate perfusion in shock states.

The dosage of Noradrenalin Aguettant is individualized and set by the prescribing clinician based on the patient’s hemodynamic status, target blood pressure, and response to therapy. Dosing is typically titrated in micrograms per minute via continuous intravenous infusion.

The safety of Noradrenalin Aguettant in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Noradrenalin Aguettant is the first‑line catecholamine vasopressor for most shock states due to its balanced alpha‑1 and beta‑1 activity. Compared with agents like dopamine or phenylephrine, it offers more predictable blood pressure control with fewer arrhythmic risks, making it the preferred choice in many guidelines.

The product should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Prior to use, inspect the solution for particulate matter and ensure the vial is within the expiry date. Maintain cold‑chain conditions during transport.

Noradrenalin Aguettant is administered intravenously as a continuous infusion. The solution is diluted in a compatible carrier fluid and infused through a dedicated line with a calibrated infusion pump, allowing precise titration to achieve the desired hemodynamic response.

Serious risks include severe hypertension, myocardial ischemia, tissue necrosis from extravasation, and rare anaphylactic reactions. Continuous cardiovascular monitoring and careful infusion site inspection are essential to detect and manage these complications promptly.

Patients with known hypersensitivity to noradrenaline or any excipients, those with pheochromocytoma, or individuals in whom uncontrolled hypertension would pose a high risk should not receive Noradrenalin Aguettant. Contraindications must be evaluated by the treating physician.